Richard William Scalzo sold $15k of DYN
SVP, Head of Finance & Admin. at Dyne Therapeutics, Inc.. 1,343 shares at an average of $11.38, traded Mar 11, 2025, filed Mar 13, 2025.
Score components
- +15RoleOfficer
- 0Trade size$15k at market
- 0Share of holdings soldSold 1.1% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -40.7%, 3m +21.7%, 6m +10.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-038731, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 11, 2025 | SOpen-market sale Common Stock10b5-1 | -1,343 | $11.38 | $15k | 122,330 | Mar 13, 2025 |
Related signals
Other insiders at Dyne Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | DYNbuy Dyne Therapeutics, Inc. | Brian S Posner director | $40k 2,500 shares | +10% | |
| 30Weak | Dyne Therapeutics, Inc. | John Cox CEO & President | $107k 5,658 shares | -2% | |
| 20Weak | Dyne Therapeutics, Inc. | Douglas Kerr Chief Medical Officer | $116k 5,035 shares | -3% | |
| 15Weak | Dyne Therapeutics, Inc. | Johanna Friedl-Naderer Chief Commercial Officer | $25k 1,085 shares | -1% | |
| 40Moderate | Dyne Therapeutics, Inc. | Jason P Rhodes director | $11M 504,695 shares | -11% | |
| 44Moderate | Dyne Therapeutics, Inc. | Erick Lucera Chief Financial Officer | $48k 2,362 shares | -2% | |
| 35Weak | Dyne Therapeutics, Inc. | Jason P Rhodes director | $5.6M 267,760 shares | -5% | |
| 35Weak | Dyne Therapeutics, Inc. | Dirk Kersten director | $5.5M 263,962 shares | -6% | |
| 35Weak | Dyne Therapeutics, Inc. | Dirk Kersten director | $1.7M 84,355 shares | -2% | |
| 27Weak | Dyne Therapeutics, Inc. | John Cox CEO & President | $49k 2,683 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.